Sickle cell trait is associated with a delayed onset of malaria: Implications for time-to-event analysis in clinical studies of malaria

Journal of Infectious Diseases

Volumn 198, Issue 9, 2008, Pages 1265-1275

  Crompton, Peter D ^a   Traore, Boubacar ^b   Kayentao, Kassoum ^b   Doumbo, Safiatou ^b   Ongoiba, Aissata ^b   Diakite, Seidina A S ^b   Krause, Michael A ^a   Doumtabe, Didier ^b   Kone, Younoussou ^b   Weiss, Greta ^a   Huang, Chiung Yu ^a   Doumbia, Seydou ^b   Guindo, Aldiouma ^b   Fairhurst, Rick M ^a   Miller, Louis H ^a   Pierce, Susan K ^a   Doumbo, Ogobara K ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF BAMAKO   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; HEMOGLOBIN; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; QUININE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD GROUP O; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROCYTE; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALARIA; MALE; MALI; PARASITEMIA; PREVALENCE; PRIORITY JOURNAL; SICKLE CELL TRAIT; THALASSEMIA;

ADOLESCENT; ADULT; BLOOD GROUP ANTIGENS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; ERYTHROCYTES; FEMALE; HEMOGLOBINS; HUMANS; MALARIA, FALCIPARUM; MALE; MULTIVARIATE ANALYSIS; PARASITEMIA; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS; SICKLE CELL TRAIT; TIME FACTORS; YOUNG ADULT;

EID: 54249152284     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/592224     Document Type: Article

References (41)

1. Moorthy V, Reed Z, Smith PG. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 2007; 25: 5115-23.
2. Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 2006; 5:127.
3. Perraut R, Marrama L, Diouf B, et al. Distinct surrogate markers for protection against Plasmodium falciparum infection and clinical malaria identified in a Senegalese community after radical drug cure. J Infect Dis 2003; 188:1940-50.
4. Meraldi V, Nebie I, Tiono AB, et al. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 2004; 26:265-72.
5. John CC, Tande AJ, Moormann AM, et al. Antibodies to preerythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis 2008; 197:519-26.
6. Moormann AM, Embury PE, Opondo J, et al. Frequencies of sickle cell trait and glucose-6-phosphate dehydrogenase deficiency differ in high-land and nearby lowland malaria-endemic areas of Kenya. Trans R Soc Trop Med Hyg 2003; 97:513-4.
7. Hill AV, Allsopp CE, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595-600.
8. Modiano D, Luoni G, Sirima BS, et al. Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature 2001; 414:305-8.
9. Williams TN, Wambua S, Uyoga S, et al. Both heterozygous and homozygous α+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood 2005; 106:368-71.
10. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med 2007; 4:e66.
11. Rowe JA, Handel IG, Thera MA, et al. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A 2007; 104:17471-6.
12. Williams TN, Mwangi TW, Wambua S, et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis 2005; 192:178-86.
13. Dicko A, Klion AD, Thera MA, et al. The etiology of severe anemia in a village and a periurban area in Mali. Blood 2004; 104:1198-200.
14. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 94(Suppl 1):S1-90.
15. Delley V, Bouvier P, Breslow N, et al. What does a single determination of malaria parasite density mean? A longitudinal survey in Mali. Trop Med Int Health 2000; 5:404-12.
16. Dicko A, Mantel C, Kouriba B, et al. Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. Trop Med Int Health 2005; 10:550-6.
17. Raper AB. Sickling in relation to morbidity from malaria and other diseases. Br Med J 1956; 1:965-6.
18. Gilles HM, Fletcher KA, Hendrickse RG, Lindner R, Reddy S, Allan N. Glucose-6-phosphate-dehydrogenase deficiency, sickling, and malaria in African children in South Western Nigeria. Lancet 1967; 1:138-40.
19. Lell B, May J, Schmidt-Ott RJ, et al. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis 1999; 28:794-9.
20. May J, Evans JA, Timmann C, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA 2007; 297:2220-6.
21. Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359: 1311-2.
22. Sokhna CS, Rogier C, Dieye A, Trape JF. Host factors affecting the delay of reappearance of Plasmodium falciparum after radical treatment among a semi-immune population exposed to intense perennial transmission. Am J Trop Med Hyg 2000; 62:266-70.
23. Coulibaly D, Diallo DA, Thera MA, et al. Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg 2002; 67:604-10.
24. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366:2012-8.
25. Bejon P, Ogada E, Mwangi T, et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2007; 2:e707.
26. Vekemans J, Ballou WR. Plasmodium falciparum malaria vaccines in development. Expert Rev Vaccines 2008; 7:223-40.
27. Friedman MJ. Erythrocytic mechanism of sickle cell resistance to malaria. Proc Natl Acad Sci U S A 1978; 75:1994-7.
28. Pasvol G, Weatherall DJ, Wilson RJ. Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria. Nature 1978; 274:701-3.
29. Luzzatto L, Nwachuku-Jarrett ES, Reddy S. Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet 1970; 1:319-21.
30. Ayi K, Turrini F, Piga A, Arese P. Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and β-thalassemia trait. Blood 2004; 104:3364-71.
31. Cabrera G, Cot M, Migot-Nabias F, Kremsner PG, Deloron P, Luty AJ. The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis 2005; 191:1631-8.
32. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989; 83:293-303.
33. Cholera R, Brittain NJ, Gillrie MR, et al. Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A 2008; 105:991-6.
34. Williams TN, Mwangi TW, Roberts DJ, et al. An immune basis for malaria protection by the sickle cell trait. PLoS Med 2005; 2:e128.
35. Njama-Meya D, Kamya MR, Dorsey G. Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health 2004; 9:862-8.
36. Males S, Gaye O, Garcia A. Long-term asymptomatic carriage of Plasmodium falciparum protects from malaria attacks: a prospective study among Senegalese children. Clin Infect Dis 2008; 46:516-22.
37. Migot-Nabias F, Mombo LE, Luty AJ, et al. Human genetic factors related to susceptibility to mild malaria in Gabon. Genes Immun 2000; 1: 435-41.
38. Parikh S, Dorsey G, Rosenthal PJ. Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg 2004; 71: 750-3.
39. Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-protective effects of α+-thalassemia and the sickle cell trait. Nat Genet 2005; 37:1253-7.
40. Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR screen for common deletional determinants of α-thalassemia. Blood 2000; 95:360-2.
41. Baysal E, Huisman TH. Detection of common deletional α-thalassemia- 2 determinants by PCR. Am J Hematol 1994; 46:208-13.